Dermaliq Therapeutics Inc.
- Biotech or pharma, therapeutic R&D
Dermaliq is a U.S.-based pharmaceutical company targeting one of dermatology’s most valuable and underserved areas: hair loss.
Our lead candidate, DLQ01™, is a novel topical therapy for androgenic alopecia (AGA) with a unique regenerative mechanism. In a recent Phase 2a trial, DLQ01 demonstrated statistically significant efficacy and excellent safety. It’s a best-in-class prospect for men and, uniquely, a first-in-class opportunity for women—a large, overlooked market with few effective treatment options.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}